Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVB-2640 in NASH (MRI-PDFF) Phase II China
CTR20192369Phase 2Completed
- Sponsor
- 3-V Biosciences, Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of denifanstat in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by 3-V Biosciences, Inc.. Started Apr 2020; status: completed.
02
Drugs
denifanstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20192369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192369.